New imaging technique for precise breast cancer surgery
Trop2-targeting the Second Near Infrared (NIR-II) Molecular Probe for the in Vitro Evaluation of Breast Cancer Surgical Margin and Sentinel Lymph Node Metastasis Status
Yunnan Cancer Hospital · NCT06713681
This study is testing a new imaging tool that helps surgeons see the difference between cancerous and healthy tissue during breast cancer surgery to improve patient outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | Female |
| Sponsor | Yunnan Cancer Hospital (other) |
| Locations | 1 site (Kunming, Yunnan) |
| Trial ID | NCT06713681 on ClinicalTrials.gov |
What this trial studies
This study evaluates a novel near-infrared (NIR-II) molecular probe, TTP-ICG, designed to enhance surgical navigation during breast cancer procedures. By using this probe, surgeons can differentiate between cancerous and non-cancerous tissues in real-time, potentially reducing positive surgical margins and improving sentinel lymph node detection. The approach involves incubating freshly excised tissues with the probe and capturing images to correlate fluorescence with pathological characteristics. The goal is to validate the effectiveness of this technique in improving surgical outcomes for breast cancer patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adult females aged 18-75 with a resectable breast nodule or mass.
Not a fit: Patients with serious underlying health conditions that contraindicate surgery or those unable to participate in the consent process may not benefit from this study.
Why it matters
Potential benefit: If successful, this technique could lead to more precise surgeries, reducing the likelihood of cancer recurrence and improving patient outcomes.
How similar studies have performed: While the use of NIR imaging in surgical settings is gaining traction, this specific approach utilizing a Trop2-targeting probe is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients between 18-75 years of age * Female * Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment * Good operative candidate * Subject capable of giving informed consent and participating in the process of consent Exclusion Criteria: * Patients unable to participate in the consent process * Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc * Other conditions that the researcher considers inappropriate to participate in the study
Where this trial is running
Kunming, Yunnan
- Yunnan Cancer Hospital — Kunming, Yunnan, China (RECRUITING)
Study contacts
- Study coordinator: Kangliang Lou, Dcotor, Doctor
- Email: 15158661275@163.com
- Phone: 86+15158661275
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Cancer, Sentinel Lymph Node, Margins of Excision, NIR-II, Trop2, Surgical navigation